|
Patient Info
Information for Patients
Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e. g., swelling of face, eyes, lips, tongue, larynx, mucous membranes, and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy. (See WARNINGS: Head and Neck Angioedema, Intestinal Angioedema and ADVERSE REACTIONS.) Text Continues Below
Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to a physi-cian. Patients should be told that if syncope occurs, MONOPRIL should be discon-tinued until the physician has been consulted. All patients should be cautioned that inadequate fluid intake or excessive perspi-ration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope. Hyperkalemia: Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the physician. Neutropenia: Patients should be told to promptly report any indication of infection (e. g., sore throat, fever), which could be a sign of neutropenia. Pregnancy: Female patients of childbearing age should be told about the conse-quences of second-and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauter-ine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.
|
.gif)
